Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints

[riky]

Sanofi, Regeneron cholesterol drug may cut heart risk, trial hints

<p><a href="http://news.yahoo.com/sanofi-regeneron-drug-cuts-cholesterol-nine-stage-trials-120654001--finance.html"><img src="http://l.yimg.com/bt/api/res/1.2/wGW0ikNG4KPhalvDo6cGZw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-07-30T120654Z_1_LYNXMPEA6T0GD_RTROPTP_2_SANOFI.JPG" width="130" height="86" alt="The Sanofi Pasteur logo is seen at the entrance of a building at tthe French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile" align="left" title="The Sanofi Pasteur logo is seen at the entrance of a building at tthe French drugmaker's vaccine unit Sanofi Pasteur plant in Marcy-l'Etoile" border="0" /></a>By Ransdell Pierson and Natalie Huet NEW YORK/PARIS (Reuters) - A new drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc significantly cut cholesterol in nine late-stage clinical trials, the companies said on Wednesday, and provided the first glimpse of its potential to prevent heart attacks and strokes. The injectable drug, alirocumab, is from a new class of medicines called PCSK9 inhibitors, which are also being developed by Amgen Inc and Pfizer Inc. If approved, they could lower &quot;bad&quot; LDL cholesterol in a new way and reap multibillion-dollar sales. An interim safety analysis of one of the Phase III studies showed patients on alirocumab were less prone, versus those on placebo, to a combination of cardiovascular events, including cardiac death, heart attack, stroke, and chest pain requiring hospitalization.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login